Compare AKR & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKR | SUPN |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 1996 | 2010 |
| Metric | AKR | SUPN |
|---|---|---|
| Price | $21.29 | $48.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $22.25 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.9M | 909.5K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $410,757,000.00 | $392,755,000.00 |
| Revenue This Year | $3.21 | $22.70 |
| Revenue Next Year | $12.17 | $19.14 |
| P/E Ratio | $96.59 | ★ N/A |
| Revenue Growth | ★ 14.20 | N/A |
| 52 Week Low | $18.06 | $32.21 |
| 52 Week High | $22.90 | $59.68 |
| Indicator | AKR | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 57.13 |
| Support Level | $20.82 | $47.48 |
| Resistance Level | $21.62 | $52.36 |
| Average True Range (ATR) | 0.37 | 1.59 |
| MACD | -0.03 | 0.50 |
| Stochastic Oscillator | 36.85 | 59.27 |
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: REIT Portfolio segment consists of high-quality retail properties located in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds the retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.